AlphaStar Capital Management’s Heart Test Laboratories HSCS Stock Holding History

AlphaStar Capital Management’s Portfolio HSCS Stock Details HSCS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-200	Closed	-$2.34K	–	317
2024 Q1	$2.34K	Sell	200 -6	-3%	-$78	﹤0.01%	286
2023 Q4	$3.52K	Buy	+206	New	+$5.07K	﹤0.01%	268

Other funds holding HSCS

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Cultivar Capital Denton, Texas $155M AUM 16.34% 1-Year Est. Return

OLVIG

Oliver Lagore Vanvalin Investment Group Flint, Michigan $255M AUM

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

AlphaStar Capital Management's HSCS Position: Q2 2024 in Review

AlphaStar Capital Management sold out of Heart Test Laboratories (HSCS) in Q2 2024, closing a stake of 200 shares — an estimated $2.34K sold.

AlphaStar Capital Management first reported a position in HSCS in Q4 2023 and held it in 2 quarters. The position peaked at $3.52K in Q4 2023. 7 funds tracked by Wall St. Rank hold HSCS as of Q2 2024.

AlphaStar Capital Management reported no remaining Heart Test Laboratories position as of Q2 2024 after selling out during the quarter.
AlphaStar Capital Management sold 200 Heart Test Laboratories shares in Q2 2024, an estimated $2.34K.
AlphaStar Capital Management first reported a position in Heart Test Laboratories in Q4 2023 and held it in 2 quarters.
AlphaStar Capital Management's Heart Test Laboratories position peaked at $3.52K in Q4 2023.
7 funds tracked by Wall St. Rank held Heart Test Laboratories as of Q2 2024.

Based on AlphaStar Capital Management's 13F filing for Q2 2024, filed 26 Jul 2024.